Illinois Medical Oncology Society

FDA approves revumenib for relapsed or refractory acute leukemia On November 15, 2024, the FDA approved revumenib (Revuforj, Syndax Pharmaceuticals, Inc.) for relapsed or refractory acute leukemia with a KMT2A translocation.

FDA approves obecabtagene autoleucel for acute lymphoblastic leukemia On November 8, 2024, the FDA approved obecabtagene autoleucel (Aucatzyl, Autolus Inc.) for relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

FDA grants accelerated approval to asciminib for CML On October 29, 2024, the FDA granted accelerated approval to asciminib (Scemblix, Novartis AG) for adult patients with newly diagnosed chronic myeloid leukemia.

IMOS Fall Medical Meeting and Board dinner with our Corporate Members was a success! Join us in April for our Practice Management Conference!

FDA approves zolbetuximab-clzb with chemotherapy On October 18, 2024, the FDA approved zolbetuximab-clzb (Vyloy, Astellas Pharma US, Inc.) with fluoropyrimidine- and platinum-containing chemotherapy for gastric or gastroesophageal junction adenocarcinoma.

FDA approves inavolisib with palbociclib and fulvestrant for endocrine On October 10, 2024, the Food and Drug Administration approved inavolisib (Itovebi, Genentech, Inc.) with palbociclib and fulvestrant for adults with endocrine-

FDA approves neoadjuvant/adjuvant nivolumab for resectable NSCLC On October 3, 2024, the FDA approved neoadjuvant/adjuvant nivolumab with platinum-doublet chemotherapy for resectable non-small cell lung cancer.

FDA approves selpercatinib for medullary thyroid cancer On September 27, 2024, the FDA granted traditional approval to selpercatinib (Retevmo, Eli Lilly and Company) for RET fusion-positive medullary thyroid cancer.

FDA approves osimertinib for non-small cell lung cancer On September 25, 2024, the FDA approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals) for non-small cell lung cancer.

Register Now -https://bit.ly/IMOS_FallMedical_Meeting2024
𝙉𝑬𝙓𝑻 𝑭𝙍𝑰𝘿𝑨𝙔!
Calling all oncology professionals!
𝑻𝒉𝒆 𝒇𝒊𝒏𝒂𝒍 𝒂𝒈𝒆𝒏𝒅𝒂 𝒇𝒐𝒓 𝒕𝒉𝒆 𝑰𝒍𝒍𝒊𝒏𝒐𝒊𝒔 𝑴𝒆𝒅𝒊𝒄𝒂𝒍 𝑶𝒏𝒄𝒐𝒍𝒐𝒈𝒚 𝑺𝒐𝒄𝒊𝒆𝒕𝒚'𝒔 𝑭𝒂𝒍𝒍 𝑴𝒆𝒅𝒊𝒄𝒂𝒍 𝑴𝒆𝒆𝒕𝒊𝒏𝒈 𝒊𝒔 𝒉𝒆𝒓𝒆, 𝒂𝒏𝒅 𝒊𝒕 𝒑𝒓𝒐𝒎𝒊𝒔𝒆𝒔 𝒕𝒐 𝒃𝒆 𝒂 𝒕𝒓𝒖𝒍𝒚 𝒔𝒕𝒂𝒏𝒅𝒐𝒖𝒕 𝒆𝒗𝒆𝒏𝒕. Join your colleagues for a half-day of learning, networking, and inspiration.
Here's why you should attend:
* 𝐈𝐭'𝐬 𝐅𝐑𝐄𝐄!
* 𝐄𝐧𝐡𝐚𝐧𝐜𝐞 𝐲𝐨𝐮𝐫 𝐬𝐤𝐢𝐥𝐥𝐬 𝐚𝐧𝐝 𝐤𝐧𝐨𝐰𝐥𝐞𝐝𝐠𝐞: Learn valuable strategies to improve patient care.
* 𝐂𝐨𝐧𝐧𝐞𝐜𝐭 𝐰𝐢𝐭𝐡 𝐩𝐞𝐞𝐫𝐬: Network with like-minded professionals, exchange ideas, and build a strong support system.
*𝐄𝐱𝐩𝐚𝐧𝐝 𝐲𝐨𝐮𝐫 𝐩𝐫𝐨𝐟𝐞𝐬𝐬𝐢𝐨𝐧𝐚𝐥 𝐧𝐞𝐭𝐰𝐨𝐫𝐤: Connect with colleagues from across the state and share insights and experiences.
*𝐏𝐋𝐔𝐒! 𝐄𝐚𝐫𝐧 𝐚 $𝟑𝟎𝟎 𝐬𝐭𝐢𝐩𝐞𝐧𝐝: Receive a valuable financial reward for attending this enriching event.
𝐃𝐨𝐧'𝐭 𝐦𝐢𝐬𝐬 𝐭𝐡𝐢𝐬 𝐭𝐫𝐚𝐧𝐬𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐯𝐞 𝐞𝐱𝐩𝐞𝐫𝐢𝐞𝐧𝐜𝐞! 𝐑𝐞𝐠𝐢𝐬𝐭𝐞𝐫 𝐍𝐨𝐰!

FDA approves Sarclisa with bortezomib, lenalidomide, and dexamethasone FDA approved isatuximab-irfc (Sarclisa, Sanofi-Aventis U.S. LLC) with bortezomib, lenalidomide, and dexamethasone for adults with diagnosed multiple myeloma

FDA approves amivantamab-vmjw with carboplatin and pemetrexed On September 19, 2024, the FDA approved amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) with carboplatin and pemetrexed for non-small cell lung cancer.

FDA approves pembrolizumab with chemotherapy for unresectable advanced On September 17, 2024, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with pemetrexed and platinum chemotherapy as first-line treatme

FDA approves Kisqali and Kisqali Femara Co-Pack On September 17, 2024, the FDA approved ribociclib (Kisqali, Novartis) and ribociclib and letrozole co-pack (Kisqali Femara Co-Pack, Novartis).

FDA approves atezolizumab and hyaluronidase-tqjs On September 12, 2024, the FDA approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc.) for subcutaneous injection.

FDA approves lazertinib with amivantamab-vmjw for NSCLC On August 19, 2024, the FDA approved lazertinib (Lazcluze, Janssen Biotech, Inc.) with amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) for NSCLC.

FDA approves neoadjuvant/adjuvant durvalumab On August 15, 2024, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) for resectable non-small cell lung cancer.

FDA approves axatilimab-csfr for chronic graft-versus-host disease On August 14, 2024, the Food and Drug Administration approved axatilimab-csfr (Niktimvo, Incyte Corporation), a colony stimulating factor-1 receptor-blocking antibody, for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adul